Medication following bariatric surgery for type 2 diabetes mellitus (BY-PLUS) study: rationale and design of a randomised controlled study

Alexis Sudlow; Alexander Dimitri Miras; Ricardo Vitor Cohen; Hassan Kahal; Jill Townley; Helen Heneghan; Carel Le Roux; Dimitri J Pournaras

doi:10.1136/bmjopen-2021-054313

Medication following bariatric surgery for type 2 diabetes mellitus (BY-PLUS) study: rationale and design of a randomised controlled study

Alexis Sudlow, Alexander Dimitri Miras, Ricardo Vitor Cohen, Hassan Kahal, Jill Townley, Helen Heneghan, Carel Le Roux, Dimitri J Pournaras

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

81 Downloads (Pure)

Abstract

INTRODUCTION: Bariatric surgery is an effective method of controlling glycaemia in patients with type 2 diabetes mellitus (T2DM) and obesity. Long-term studies suggest that although glycaemic control remains good, only 20%-40% of patients will maintain remission according to the American Diabetes Association criteria.

PURPOSE: This trial aims to examine the safety and efficacy of combining Roux-en-Y gastric bypass or sleeve gastrectomy with goal-directed medical therapy to improve long-term glycaemic control of T2DM.

METHODS AND ANALYSIS: This prospective, open-label multicentre randomised controlled trial (RCT) will recruit 150 patients with obesity and T2DM from tertiary care obesity centres. Patients will be randomised 1:1 to receive either bariatric surgery and standard medical care or bariatric surgery and intensive goal-directed medical therapy, titrated to specific targets for glycated haemoglobin (HbA1c), blood pressure (BP) and low-density lipoproteins (LDL) cholesterol. The primary endpoints are the proportion of patients in each arm with an HbA1c<6.5% (48 mmol/mol) at 1 year and the proportion of patients in each arm achieving the composite endpoint of HbA1c<6.5% (48 mmol/mol), BP<130/80 mm Hg and LDL<2.6 mmol/L at 5 years.

ETHICS AND DISSEMINATION: The local institutional review board approved this study. This study represents the first RCT to examine the safety and efficacy of combining bariatric surgery with intensive medical therapy compared with bariatric surgery and usual care for long-term diabetes control.

TRIAL REGISTRATION NUMBER: NCT04432025.

Original language	English
Article number	e054313
Pages (from-to)	1-10
Number of pages	10
Journal	BMJ Open
Volume	12
Issue number	7
Early online date	25 Jul 2022
DOIs	https://doi.org/10.1136/bmjopen-2021-054313
Publication status	Published online - 25 Jul 2022

Bibliographical note

Funding Information:
AS and DJP received funding from the Royal College of Surgeons (England) for this work. Grant number: PO117623.

Funding Information:
RVC has received an honorarium as a member of the Speaker’s panel of Johnson & Johnson. CLR has received grants from the Science Foundation Ireland, Health Research Board, Irish Research Council, Johnson & Johnson and AnaBio. Personal fees have been received from Eli Lily, Johnson & Johnson, Sanofi Aventis, Astra Zeneca, Janssen, Bristol-Meyers Squibb and Boehringer-Ingelheim. He is on the advisory board for GI dynamics. DJP has received personal fees from NovoNordisk and Johnson & Johnson.

Publisher Copyright:
© 2022 BMJ Publishing Group. All rights reserved.

Keywords

Diabetes and endocrinology
1506
1843
DIABETES & ENDOCRINOLOGY
General diabetes
SURGERY

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/bmjopen-2021-054313

bmjopen-2021-054313.pdfFinal published version, 323 KBLicence: CC BY

Cite this

@article{23d71d7153d64c1eafde9c01c6a72731,

title = "Medication following bariatric surgery for type 2 diabetes mellitus (BY-PLUS) study: rationale and design of a randomised controlled study",

abstract = "INTRODUCTION: Bariatric surgery is an effective method of controlling glycaemia in patients with type 2 diabetes mellitus (T2DM) and obesity. Long-term studies suggest that although glycaemic control remains good, only 20%-40% of patients will maintain remission according to the American Diabetes Association criteria.PURPOSE: This trial aims to examine the safety and efficacy of combining Roux-en-Y gastric bypass or sleeve gastrectomy with goal-directed medical therapy to improve long-term glycaemic control of T2DM.METHODS AND ANALYSIS: This prospective, open-label multicentre randomised controlled trial (RCT) will recruit 150 patients with obesity and T2DM from tertiary care obesity centres. Patients will be randomised 1:1 to receive either bariatric surgery and standard medical care or bariatric surgery and intensive goal-directed medical therapy, titrated to specific targets for glycated haemoglobin (HbA1c), blood pressure (BP) and low-density lipoproteins (LDL) cholesterol. The primary endpoints are the proportion of patients in each arm with an HbA1c<6.5% (48 mmol/mol) at 1 year and the proportion of patients in each arm achieving the composite endpoint of HbA1c<6.5% (48 mmol/mol), BP<130/80 mm Hg and LDL<2.6 mmol/L at 5 years.ETHICS AND DISSEMINATION: The local institutional review board approved this study. This study represents the first RCT to examine the safety and efficacy of combining bariatric surgery with intensive medical therapy compared with bariatric surgery and usual care for long-term diabetes control.TRIAL REGISTRATION NUMBER: NCT04432025.",

keywords = "Diabetes and endocrinology, 1506, 1843, DIABETES & ENDOCRINOLOGY, General diabetes, SURGERY",

author = "Alexis Sudlow and Miras, {Alexander Dimitri} and Cohen, {Ricardo Vitor} and Hassan Kahal and Jill Townley and Helen Heneghan and {Le Roux}, Carel and Pournaras, {Dimitri J}",

note = "Funding Information: AS and DJP received funding from the Royal College of Surgeons (England) for this work. Grant number: PO117623. Funding Information: RVC has received an honorarium as a member of the Speaker{\textquoteright}s panel of Johnson & Johnson. CLR has received grants from the Science Foundation Ireland, Health Research Board, Irish Research Council, Johnson & Johnson and AnaBio. Personal fees have been received from Eli Lily, Johnson & Johnson, Sanofi Aventis, Astra Zeneca, Janssen, Bristol-Meyers Squibb and Boehringer-Ingelheim. He is on the advisory board for GI dynamics. DJP has received personal fees from NovoNordisk and Johnson & Johnson. Publisher Copyright: {\textcopyright} 2022 BMJ Publishing Group. All rights reserved.",

year = "2022",

month = jul,

day = "25",

doi = "10.1136/bmjopen-2021-054313",

language = "English",

volume = "12",

pages = "1--10",

journal = "BMJ Open",

issn = "2044-6055",

publisher = "BMJ Publishing Group",

number = "7",

}

TY - JOUR

T1 - Medication following bariatric surgery for type 2 diabetes mellitus (BY-PLUS) study: rationale and design of a randomised controlled study

AU - Sudlow, Alexis

AU - Miras, Alexander Dimitri

AU - Cohen, Ricardo Vitor

AU - Kahal, Hassan

AU - Townley, Jill

AU - Heneghan, Helen

AU - Le Roux, Carel

AU - Pournaras, Dimitri J

N1 - Funding Information: AS and DJP received funding from the Royal College of Surgeons (England) for this work. Grant number: PO117623. Funding Information: RVC has received an honorarium as a member of the Speaker’s panel of Johnson & Johnson. CLR has received grants from the Science Foundation Ireland, Health Research Board, Irish Research Council, Johnson & Johnson and AnaBio. Personal fees have been received from Eli Lily, Johnson & Johnson, Sanofi Aventis, Astra Zeneca, Janssen, Bristol-Meyers Squibb and Boehringer-Ingelheim. He is on the advisory board for GI dynamics. DJP has received personal fees from NovoNordisk and Johnson & Johnson. Publisher Copyright: © 2022 BMJ Publishing Group. All rights reserved.

PY - 2022/7/25

Y1 - 2022/7/25

N2 - INTRODUCTION: Bariatric surgery is an effective method of controlling glycaemia in patients with type 2 diabetes mellitus (T2DM) and obesity. Long-term studies suggest that although glycaemic control remains good, only 20%-40% of patients will maintain remission according to the American Diabetes Association criteria.PURPOSE: This trial aims to examine the safety and efficacy of combining Roux-en-Y gastric bypass or sleeve gastrectomy with goal-directed medical therapy to improve long-term glycaemic control of T2DM.METHODS AND ANALYSIS: This prospective, open-label multicentre randomised controlled trial (RCT) will recruit 150 patients with obesity and T2DM from tertiary care obesity centres. Patients will be randomised 1:1 to receive either bariatric surgery and standard medical care or bariatric surgery and intensive goal-directed medical therapy, titrated to specific targets for glycated haemoglobin (HbA1c), blood pressure (BP) and low-density lipoproteins (LDL) cholesterol. The primary endpoints are the proportion of patients in each arm with an HbA1c<6.5% (48 mmol/mol) at 1 year and the proportion of patients in each arm achieving the composite endpoint of HbA1c<6.5% (48 mmol/mol), BP<130/80 mm Hg and LDL<2.6 mmol/L at 5 years.ETHICS AND DISSEMINATION: The local institutional review board approved this study. This study represents the first RCT to examine the safety and efficacy of combining bariatric surgery with intensive medical therapy compared with bariatric surgery and usual care for long-term diabetes control.TRIAL REGISTRATION NUMBER: NCT04432025.

AB - INTRODUCTION: Bariatric surgery is an effective method of controlling glycaemia in patients with type 2 diabetes mellitus (T2DM) and obesity. Long-term studies suggest that although glycaemic control remains good, only 20%-40% of patients will maintain remission according to the American Diabetes Association criteria.PURPOSE: This trial aims to examine the safety and efficacy of combining Roux-en-Y gastric bypass or sleeve gastrectomy with goal-directed medical therapy to improve long-term glycaemic control of T2DM.METHODS AND ANALYSIS: This prospective, open-label multicentre randomised controlled trial (RCT) will recruit 150 patients with obesity and T2DM from tertiary care obesity centres. Patients will be randomised 1:1 to receive either bariatric surgery and standard medical care or bariatric surgery and intensive goal-directed medical therapy, titrated to specific targets for glycated haemoglobin (HbA1c), blood pressure (BP) and low-density lipoproteins (LDL) cholesterol. The primary endpoints are the proportion of patients in each arm with an HbA1c<6.5% (48 mmol/mol) at 1 year and the proportion of patients in each arm achieving the composite endpoint of HbA1c<6.5% (48 mmol/mol), BP<130/80 mm Hg and LDL<2.6 mmol/L at 5 years.ETHICS AND DISSEMINATION: The local institutional review board approved this study. This study represents the first RCT to examine the safety and efficacy of combining bariatric surgery with intensive medical therapy compared with bariatric surgery and usual care for long-term diabetes control.TRIAL REGISTRATION NUMBER: NCT04432025.

KW - Diabetes and endocrinology

KW - 1506

KW - 1843

KW - DIABETES & ENDOCRINOLOGY

KW - General diabetes

KW - SURGERY

UR - http://www.scopus.com/inward/record.url?scp=85135078242&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2021-054313

DO - 10.1136/bmjopen-2021-054313

M3 - Article

C2 - 35879015

SN - 2044-6055

VL - 12

SP - 1

EP - 10

JO - BMJ Open

JF - BMJ Open

IS - 7

M1 - e054313

ER -

Medication following bariatric surgery for type 2 diabetes mellitus (BY-PLUS) study: rationale and design of a randomised controlled study

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this